WO2015186721A1 - Anticorps ou fragment d'anticorps comprenant une région variable de celui-ci, polypeptide antigénique et utilisations de ceux-ci - Google Patents

Anticorps ou fragment d'anticorps comprenant une région variable de celui-ci, polypeptide antigénique et utilisations de ceux-ci Download PDF

Info

Publication number
WO2015186721A1
WO2015186721A1 PCT/JP2015/065986 JP2015065986W WO2015186721A1 WO 2015186721 A1 WO2015186721 A1 WO 2015186721A1 JP 2015065986 W JP2015065986 W JP 2015065986W WO 2015186721 A1 WO2015186721 A1 WO 2015186721A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
variable region
amino acid
acid sequence
Prior art date
Application number
PCT/JP2015/065986
Other languages
English (en)
Japanese (ja)
Inventor
裕子 内田
岳彦 西藤
鈴木　康司
雄二 庄屋
雅義 豊浦
有希子 石田
Original Assignee
国立研究開発法人農業・食品産業技術総合研究機構
株式会社ファーマフーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立研究開発法人農業・食品産業技術総合研究機構, 株式会社ファーマフーズ filed Critical 国立研究開発法人農業・食品産業技術総合研究機構
Priority to JP2016525195A priority Critical patent/JP6525214B2/ja
Publication of WO2015186721A1 publication Critical patent/WO2015186721A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Definitions

  • the present invention relates to antibody fragments comprising an antibody or its variable region, antigenic polypeptides, and uses thereof.
  • H5 subtype highly pathogenic avian influenza virus including H5N1 subtype highly pathogenic avian influenza virus (HPAIV) causes outbreak of avian influenza in poultry from 2003 onwards, aspect of localization mainly in Asia It is When such highly pathogenic avian influenza virus infects birds and the infection spreads, it causes great damage to the livestock industry and the like, and there is also a fear of human infection. Since HPAIV's epidemic prevention in Japan is based on a cover-up investigation, early detection at the field level is important. At present, as a test system that is simply used in the field, one that detects influenza A virus is used, but it is not one that rapidly determines H5N1 subtype highly pathogenic avian influenza.
  • a diagnostic kit using influenza nucleoprotein as a target antigen is mentioned, but there is a problem that it has no H5N1 avian influenza virus specificity and also responds to other influenza viruses.
  • Other examples include a diagnostic kit using recombinant H5 hemagglutinin (HA, virus hemagglutinin) protein of H5N1 subtype inactivated virus as a target antigen, but because an antibody against an immunodominant antigen can be produced, the virus If there is a mutation in the gene, there is a problem that the reactivity may be reduced or undetectable. Therefore, development of a diagnostic reagent for H5 subtype avian influenza virus infection is desired. In order to develop an effective diagnostic reagent, it is necessary to produce an antibody that broadly recognizes the H5 subtype avian influenza virus.
  • Patent Document 1 describes a monoclonal antibody that specifically binds to HA envelope glycoprotein of H5 subtype avian influenza virus or neuraminidase glycoprotein of N1 subtype.
  • Patent Document 2 describes a monoclonal antibody and the like which can recognize and bind an epitope in the HA2 subunit of HA, and have a neutralizing activity against the H5 subtype avian influenza virus.
  • Patent Document 3 describes an isolated monoclonal antibody that binds to an epitope of the stem region of the avian influenza virus HA protein and neutralizes influenza A virus including H5N1 subtype.
  • evaluation of antibody activity is carried out by virus neutralization test. For example, it is carried out by testing the presence or absence of HA protein activity by a hemagglutination inhibition test or the like. That is, when the antibody in the prior art infects a human etc., it aims at neutralizing the H5N1 subtype avian influenza virus using the said antibody. Therefore, even if these antibodies are used as detection reagents, if a mutation occurs in the virus, there is a high possibility that the reactivity of the antibody is lost and the virus can not be detected.
  • hemagglutinin hemagglutinin, HA
  • HA hemagglutinin
  • the present invention includes any one of the following aspects.
  • ⁇ 1> An antibody or a variable region thereof characterized by specifically binding to a hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 in the hemagglutinin HA1 region of H5 subtype avian influenza virus Antibody fragment.
  • a method for producing an antibody that specifically binds to a hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 of the hemagglutinin HA1 region of H5 subtype avian influenza virus which comprises the following (a A) a method comprising the steps of (c): (a) immunizing the avian hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 with a bird; (b) the above step (a) Obtaining a phage antibody library comprising a phage antibody which specifically binds to the above-mentioned hemagglutinin HA1 antigen polypeptide from the birds immunized with the above; and (c) the above-mentioned hemagglutinin HA1 among the phage antibodies obtained in the above step (b) Concentrating and selecting antibodies that specifically bind to the antigenic polypeptide.
  • the antibody according to the present invention and the antibody fragment containing the variable region exhibit an excellent effect of specifically binding to H5 subtype avian influenza virus and not binding to other subtypes of avian influenza virus other than H5. . Therefore, H5 subtype avian influenza virus can be detected accurately, rapidly and simply by using the antibody according to the present invention.
  • Figure 7 shows the steps of immunization of a chicken and preparation of a scFv phage antibody library from immunized chicken spleen. It is a figure which shows 1 process in the preparation methods of the antibody based on Example 1 of this invention. The process of panning selection of scFv phage library is shown. It is a figure which shows 1 process in the preparation methods of the antibody based on Example 1 of this invention. The steps of screening an scFv phage library using ELISA are shown. It is a figure which shows the variable region of the amino acid sequence of the obtained wild type single chain antibody based on Example 1 of this invention.
  • FIG. 6 shows the results of CBB staining of a wild-type bivalent antibody protein according to Example 1 of the present invention after electrophoresis. It is a figure which shows the antibody titer of the wild type bivalent antibody based on Example 1 of this invention. It is a figure which shows the antibody binding property with respect to the variant of H5N1 subtype avian influenza virus of the wild type bivalent antibody, and two or more types of subtype avian influenza viruses other than H5 based on Example 1 of this invention.
  • polynucleotide may also be referred to as “nucleic acid” or “nucleic acid molecule” and is intended to be a polymer of nucleotides.
  • Base sequence can also be referred to as “nucleic acid sequence” or “nucleotide sequence”, and unless otherwise stated, is intended the sequence of deoxyribonucleotides or the sequence of ribonucleotides.
  • the polynucleotide may be single-stranded or double-stranded, and in the case of single-stranded polynucleotide, it may be a sense strand or an antisense strand.
  • polypeptide can also be referred to as “protein” or “protein fragment”.
  • H5 subtype avian influenza virus and “H5N1 subtype avian influenza virus” refer to a type of avian influenza virus subtype.
  • Avian influenza viruses are classified according to their nuclear and matrix protein antigen specificity. Avian influenza virus is mainly classified into A, B and C serotypes. Among these, type A avian influenza virus has eight RNA segments and encodes ten viral proteins.
  • Hemagglutinin refers to the envelope glycoprotein of influenza virus. HA enables adsorption and entry of influenza virus into host cells.
  • Neuroaminidase (hereinafter referred to as "NA”) has a function of cleaving sialic acid when virus particles leave the cell surface at the late stage of infection, and plays a role in acquiring infectivity.
  • influenza A viruses are derived from birds, and influenza viruses of type A are further classified into subtypes by the antigenic nature of HA and NA.
  • HA has 16 subtypes of H1 to H16, and NA has 9 subtypes of N1 to N9.
  • H5 and H7 subtypes of influenza viruses are not highly pathogenic to the natural host waterfowl, but exhibit high virulence that causes death when infected with poultry such as chickens It is known that it is called highly pathogenic avian influenza virus (HPAIV). Furthermore, in recent years, cases of human infection have been successively reported from the outbreak of influenza caused by H5N1 subtype virus infection in poultry. From such a situation, there is concern that H5N1 subtype HPAIV is mutated so as to be able to efficiently infect human to human, and it becomes a novel influenza virus.
  • HPAIV highly pathogenic avian influenza virus
  • the H5N1 avian influenza virus which has been localized to poultry in Asia in recent years, can be further classified into multiple clades based on the homology of the base sequences of the HA gene. Accession number (Accession) in the GenBank database (web page: http://www.ncbi.nlm.nih.gov/genbank/) provided by the National Center for Biotechnology Information (NCBI).
  • NCBI National Center for Biotechnology Information
  • HA gene of H5N1 subtype HPAIV registered by No. is classified into clades 0 to 9 and further sub-clades thereof by WHO / OIE / FAO H5N1 Evolution Working Group.
  • the “HA1 region” and the “HA2 region” respectively indicate two regions flanking the proteolytic cleavage site of the hemagglutinin protein (HA) of influenza virus and the fusion peptide region linked thereto. Moreover, proteolytic cleavage at the HA1-HA2 junction of the HA protein is associated with viral proliferative properties, and the continuous presence of hydrophobic amino acids around this cleavage site is characteristic of HPAIV . And the HA1 and HA2 regions are responsible for the high virulence in chickens.
  • HA hemagglutinin protein
  • sequence identity across the HA1 region between all clades in the H5N1 subtypes described above is 91-99 for all different clade combinations, using those listed above for each clade strain. % Sequence identity.
  • sequence identity across the HA1 region among all the H1 to H16 subtypes is in the range of 7 to 51% for any combination of different subtypes.
  • sequence identity between the entire HA1 region of each of the H1 to H4 subtypes and the H6 to H16 subtypes and the entire HA1 region of the H5 type is very low, all in the range of 8% to 21%.
  • sequence identity across the HA2 region between all clades in the above mentioned H5N1 subtypes is 94 to 100% in all clade combinations, using the ones listed above for each clade strain Have the sequence identity of
  • sequence identity across the HA1 region between all H1 to H16 subtypes is in the range of 42 to 81% for any combination of different subtypes.
  • sequence identity between the entire HA2 region of each of the H1 to H4 type and the H6 to H16 subtype and the entire HA2 region of the H5 subtype is 45 to 75%.
  • bivalent antibody means an antibody having two antigen binding sites per molecule, that is, an antibody having a bivalent binding to an antigen.
  • the above “bivalent antibody” is composed of two light chains (a light chain variable region and a light chain constant region) and two heavy chains (a heavy chain variable region and a heavy chain constant region) which are respectively homologous to each other and which are disulfide linked (S An antibody having a structure bound by -S bond).
  • the antibody molecule be a full-length antibody molecule, and a “bivalent antibody” as long as it has a structure in which two heavy chains can be linked by S—S bond, ie, a structure having at least F (ab ′) 2 fragment It is included in the category of
  • single-chain variable fragment refers to a light chain (also referred to as L chain) variable region and a heavy chain (Heavy chain, H) It refers to an antibody in which one variable region is linked to a variable region (also referred to as a chain) and two variable regions are close to form one antigen binding site.
  • the above “single-chain variable region fragment” is an antibody having one antigen binding site per molecule. For example, it refers to an antibody obtained by an antibody production method using phage display. Also described herein as “single chain antibodies”.
  • a and / or B is a concept including both A and B and A or B, and can be reworded as “at least one of A and B”.
  • HA1 antigen polypeptide according to the present invention may be a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10.
  • the HA1 antigen polypeptide according to the present invention may be a polypeptide consisting of 15 or more and 16 or less consecutive amino acids in a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10.
  • a “linker peptide to the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10” May be added, other amino acids or proteins may be linked (for example, a tagged protein or a fusion protein).
  • the linker polypeptide linked to the HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 includes a polypeptide consisting of 10 to 25 amino acids, etc.
  • the tag includes His tag, Myc tag and Flag tag etc. are mentioned.
  • the method for producing the HA1 antigen polypeptide according to the present invention may be chemical synthesis or may use an expression vector.
  • the HA1 antigen polypeptide of the present invention can be produced by known polypeptide synthesis methods.
  • polypeptide synthesis methods include, but are not limited to, chemical synthesis methods such as liquid phase polypeptide synthesis methods and solid phase peptide synthesis methods.
  • the polypeptide may be produced from a transformant into which the expression vector has been introduced, or may be produced using an in vitro translation system.
  • a target polypeptide can be produced in a host cell into which an expression vector into which a polynucleotide encoding the amino acid sequence shown in SEQ ID NO: 10 has been inserted has been introduced.
  • an expression vector into which a polynucleotide encoding the amino acid sequence shown in SEQ ID NO: 10 has been inserted has been introduced.
  • the method described in the item of recombinant vector] is preferably used.
  • the transformant for example, the following [5.
  • the method described in item [transformant] is used for example.
  • the HA1 antigen polypeptide according to the present invention is preferably stably expressed in the host cell, but may be transiently expressed.
  • the polypeptide thus produced can be purified according to known methods.
  • the method for purifying the polypeptide is not particularly limited, and examples thereof include gel filtration chromatography, ion exchange chromatography, affinity chromatography and the like.
  • the HA1 antigen polypeptide according to the present invention is very highly retained among strains having different H5N1 subtypes among the amino acid sequences of the HA1 region of the H5N1 avian influenza virus virus, as shown in Examples and FIG. And it is the amino acid sequence of the site
  • the sequence identity of the amino acid sequence corresponding to this amino acid sequence is very low. That is, the HA1 antigen polypeptide according to the present invention is resistant to mutation even in the host, and is structurally very excellent in its ability to bind to an antibody. Therefore, the HA1 antigen polypeptide according to the present invention can be suitably used for the production of an antibody very specific for the H5N1 avian influenza virus.
  • Antibody according to the present invention and antibody fragment containing the variable region thereof specifically bind to a hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 in the HA1 region of H5 subtype avian influenza virus. It features.
  • HA1 antigen polypeptide specifically binds to HA1 antigen polypeptide means to recognize and bind to the sequence of the HA1 antigen polypeptide, and includes, for example, the sequence of the HA1 antigen polypeptide, It also binds to polypeptides having longer sequences.
  • antibody means immunoglobulin (IgA, IgD, IgE, IgY, IgG, IgM and Fab fragments thereof, F (ab ') 2 fragment, Fc fragment) thereof, for example, a monoclonal antibody
  • bivalent antibodies such as polyclonal antibodies, anti-idiotype antibodies, chimerized antibodies, humanized antibodies and single chain variable region fragments and peptides including the complementarity determining regions (CDRs) of the antibodies, etc. It is not limited to these.
  • an antibody fragment of the present invention which comprises the variable region of the above antibody, is also included in the scope of the present invention.
  • the antibody fragment is not particularly limited as long as it is an antibody fragment containing the variable region of the above-mentioned antibody and recognizes the H5 subtype avian influenza virus.
  • Such an antibody fragment may be a fragment of any of the full-length H chain, full-length L chain, variable region of H chain, and variable region of L chain of the antibody of the present invention.
  • Such antibody fragments can be suitably used, for example, in flow cytometry or ELISA.
  • antibody fragments can be suitably used to produce chimeric antibodies by transplantation into antibodies of human or other animals.
  • one embodiment of the antibody according to the present invention and an antibody fragment containing the variable region thereof is specific for consecutive 15 or more and 16 or less amino acids in the HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 Bond to
  • specific binding of the antibody fragment containing the above-mentioned antibody or its variable region to the HA1 antigen polypeptide may occur in one specific region in the HA1 antigen polypeptide, or at two or more places. It may occur simultaneously in different areas.
  • One aspect of the antibody according to the present invention is a bivalent antibody in which the H chain consists of the amino acid sequence shown in SEQ ID NO: 26 and the L chain consists of the amino acid sequence shown in SEQ ID NO: 28.
  • another example of the antibody according to the present invention is a bivalent antibody in which the H chain consists of the amino acid sequence shown in SEQ ID NO: 52 and the L chain consists of the amino acid sequence shown in SEQ ID NO: 28.
  • the amino acid sequence shown in SEQ ID NO: 2 is the amino acid sequence of the H chain variable region of the antibody according to one aspect of the present invention
  • the amino acid sequence shown in SEQ ID NO: 3 is the L chain of the antibody according to one aspect of the present invention It is an amino acid sequence of a variable region.
  • FIG. 4 shows the amino acid sequence of the H chain variable region and the amino acid sequence of the L chain variable region of the antibody according to one aspect of the present invention.
  • the H chain variable region of the antibody according to one embodiment of the present invention has CDR1, CDR2 and CDR3 which are regions of CDRs shown by squares.
  • the heavy chain variable region of the antibody according to one aspect of the present invention consists of the amino acid sequence of 1st to 130th amino acid sequences shown in SEQ ID NO: 1 and CDR1 consisting of the 31st to 35th amino acid sequences;
  • the CDR2 consists of the 50th to 66th amino acid sequence of the amino acid sequence shown in SEQ ID NO: 1 and the CDR3 consists of the 99th to 119th amino acid sequence of the amino acid sequence shown in SEQ ID NO: 1.
  • the light chain variable region of the antibody according to one aspect of the present invention has CDR1, CDR2 and CDR3 which are indicated by a box.
  • the L chain variable region of the antibody according to one aspect of the present invention consists of the amino acid sequence 148 to 270 of the amino acid sequence shown in SEQ ID NO: 1, and the amino acid 168 to 176 in the amino acid sequence shown in SEQ ID NO: 1 It has CDR1 consisting of the sequence, CDR2 consisting of the amino acid sequence 193 to 203 of the amino acid sequence shown in SEQ ID NO: 1, and CDR3 consisting of the amino acid sequence 232 to 240 of the amino acid sequence shown in SEQ ID NO: 1.
  • the antibody of one embodiment of the present invention is an antibody consisting of the amino acid sequence shown in SEQ ID NO: 1.
  • the antibody of another aspect of the present invention comprises the amino acid sequence of which the heavy chain variable region is shown in SEQ ID NO: 45, and the amino acid sequence of which the light chain variable region is shown in SEQ ID NO: 3. Furthermore, an antibody of another aspect of the present invention is an antibody consisting of the amino acid sequence shown in SEQ ID NO: 44.
  • amino acid sequences of CDR1, CDR2 and CDR3 of the H chain variable region of the antibody according to one aspect of the present invention are shown in SEQ ID NOs: 4 to 6, respectively, and amino acids of CDR1, CDR2 and CDR3 of the L chain variable region of the antibody according to the present invention The sequences are shown in SEQ ID NOs: 7-9, respectively.
  • amino acid sequence and nucleotide sequence of CDR3 of the H chain variable region of the antibody according to another aspect of the present invention are shown in SEQ ID NOs: 46 and 47, respectively.
  • another embodiment of the antibody according to the present invention comprises all of CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5 and CDR3 shown in SEQ ID NO: 6 in the H chain variable region, And an antibody fragment comprising an antibody or its variable region, having all of CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8 and CDR3 shown in SEQ ID NO: 9 in the L chain variable region. is there.
  • still another embodiment of the antibody according to the present invention comprises all of CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5 and CDR3 shown in SEQ ID NO: 46 in the H chain variable region. And an antibody fragment comprising an antibody or its variable region, having all of CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8 and CDR3 shown in SEQ ID NO: 9 in the L chain variable region It is.
  • still another embodiment of the antibody according to the present invention is the CDR1 represented by SEQ ID NO: 4, the CDR2 represented by SEQ ID NO: 5 and the CDR3 represented by SEQ ID NO: 6 or SEQ ID NO: 46 in the H chain variable region. And at least one of CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8 and CDR3 shown in SEQ ID NO: 9 in the L chain variable region An antibody or an antibody fragment containing the variable region thereof.
  • still another embodiment of the antibody according to the present invention is the CDR1 represented by SEQ ID NO: 4, the CDR2 represented by SEQ ID NO: 5 and the CDR3 represented by SEQ ID NO: 6 or SEQ ID NO: 46 in the H chain variable region. Or at least one of CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8 and CDR3 shown in SEQ ID NO: 9 in the L chain variable region An antibody or an antibody fragment containing the variable region thereof.
  • the antibody according to the present invention or an antibody fragment containing the variable region thereof also includes those having the following characteristics.
  • the H chain variable region is 1 to 13, preferably 1 to 6, more preferably 1 to 2 or 3 More preferably, one amino acid consists of a substituted, deleted, inserted and / or added amino acid sequence, and the light chain variable region is shown in the amino acid sequence shown in SEQ ID NO: 3 or in SEQ ID NO: 3 Amino acid in which 1 to 10, preferably 1 to 5, more preferably 1 to 2 or 3 and even more preferably 1 amino acid is substituted, deleted, inserted and / or added in the amino acid sequence An antibody or an antibody fragment comprising a variable region thereof consisting of a sequence.
  • an antibody according to the present invention and an antibody fragment containing the variable region thereof is an antibody or antibody wherein the heavy chain variable region consists of the amino acid sequence shown in SEQ ID NO: 2 and the light chain variable region consists of the amino acid sequence shown in SEQ ID NO: 3 Mention may be made of antibody fragments comprising the variable region.
  • Another example of the antibody according to the present invention and an antibody fragment containing the variable region thereof, wherein the heavy chain variable region consists of the amino acid sequence shown in SEQ ID NO: 45 and the light chain variable region is the amino acid shown in SEQ ID NO: 3 Mention may be made of an antibody consisting of a sequence or an antibody fragment comprising the variable region thereof.
  • the amino acid sequence shown in SEQ ID NO: 45 the 105th amino acid Y of the amino acid sequence shown in SEQ ID NO: 2 is substituted with R, the 106th amino acid S with R, and the 107th amino acid Y with V Sequence.
  • An antibody having such a sequence has higher reactivity to the HA1 antigen while maintaining its specificity for the H5 subtype avian influenza virus, which is more preferable.
  • an antibody fragment according to the present invention or an antibody fragment containing the variable region thereof specifically binds to a hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 in the hemagglutinin HA1 region of H5 subtype avian influenza virus Or an antibody fragment containing the variable region thereof, which is shown in any of the following (1) to (4): (1) An antibody consisting of the amino acid sequence shown in SEQ ID NO: 1 or 44 or an antibody fragment containing the variable region thereof (2) An antibody fragment comprising an amino acid sequence in which 1 to 35 amino acids are substituted, deleted, inserted and / or added in the amino acid sequence shown in SEQ ID NO: 1 or 44, or an antibody fragment comprising the variable region thereof (3) An antibody fragment having a sequence identity of 90% or more to the amino acid sequence shown in SEQ ID NO: 1 or 44, or an antibody fragment comprising the variable region thereof (4) A polynucleotide that hybridizes under stringent conditions to a polynucleo
  • one aspect of the antibody according to the present invention is obtained by the production method including the steps of (a) to (c) shown below.
  • the antibody according to the present invention and the antibody fragment containing the variable region thereof are a single chain variable region fragment or a bivalent antibody, preferably a bivalent antibody.
  • Examples of single chain antibodies encompassed by the present invention include antibodies consisting of the amino acid sequence shown in SEQ ID NO: 44.
  • amino acids 252 to 351 of the amino acid sequence shown in SEQ ID NO: 1 to amino acids 252 to 359 in the amino acid sequence shown in SEQ ID NO: 44 The antibody which consists of the substituted amino acid sequence is mentioned.
  • amino acids 252 to 359 of the amino acid sequence shown in SEQ ID NO: 44 are the amino acids 252 to 351 of the amino acid sequence shown in SEQ ID NO: 1
  • an example of the bivalent antibody according to the present invention is a bivalent mouse chimeric anti-HA1 antibody having the following characteristics: a variable region derived from a chicken and a constant region derived from a mouse IgG1, which is an immunoglobulin The subtype is IgG1 and the molecular weight is about 150 kDa.
  • a further specific example of the bivalent antibody according to the present invention is that in which the H chain consists of the amino acid sequence shown in SEQ ID NO: 26 and the L chain consists of the amino acid sequence shown in SEQ ID NO: 28. Furthermore, as another example of a more preferable bivalent antibody according to the present invention, one in which the H chain consists of the amino acid sequence shown in SEQ ID NO: 52 and the L chain consists of the amino acid sequence shown in SEQ ID NO: 28 Be
  • the antibody according to the present invention and the antibody fragment containing the variable region also encompass an antibody labeled with a labeling agent.
  • the labeled antibody has the following [7. Kit according to the present invention] and [8. Method for detecting H5 subtype avian influenza virus].
  • Examples of the above-mentioned labeling agent include enzymes, enzyme substrates, radioactive isotopes, luminescent substances, fluorescent substances, biotin, coloring substances and the like.
  • Examples of enzymes include peroxidase, ⁇ -galactosidase, alkaline phosphatase, glucose oxidase, acetylcholinesterase and glucose-6-phosphate dehydrogenase. Coupling between these enzymes and antibodies can be carried out by known methods using crosslinking agents such as maleimide compounds and N-hydroxysuccinimide ester compounds.
  • As the enzyme substrate known substances can be used depending on the enzyme used.
  • OPD orthophenylenediamine
  • TMB tetramethylbenzidine
  • nitro blue tetrazolium (NBT) and 5-bromo- A mixed substrate of 4-chloro-3-indolylphosphatase p-toluidinyl salt (BCIP) or the like can be used.
  • radioactive isotopes those used in conventional radioimmunoassays such as 125 I, 3 H or 35 S can be used.
  • Radiolabeling to the antibody according to the present invention can be performed using a known method.
  • the fluorescent dye those used for ordinary fluorescent antibody methods such as fluorescein isothiocyanate, tetramethylrhodamine isothiocyanate and phycoerythrin can be used.
  • fluorescent silica nanoparticles may be used as the fluorescent material.
  • the light emitting substance isoluminol, acridine ester, lucigenin or the like can be used.
  • a known method can be used as a method of labeling.
  • a coloring latex particle, a gold colloid, etc. can be mentioned, for example.
  • the antibody according to the present invention and an antibody fragment containing the variable region thereof may be immobilized on a solid support.
  • Solid supports that can be used include polystyrene, polycarbonate, polypropylene or polyvinyl microtiter plates, test tubes, capillaries, beads (such as latex particles and metal compounds), membranes (such as liposomes) and filters.
  • polystyrene is particularly preferred.
  • the antibody thus immobilized is, for example, described later [8. [Method for detecting H5 subtype avian influenza virus]
  • the antibody according to the present invention and the antibody fragment containing the variable region thereof are highly retained among strains differing in H5 subtype among the amino acid sequences of HA1 region of H5 subtype avian influenza virus It binds to the site exposed to the surface of the H5 subtype avian influenza virus protein in a three-dimensional structure. Furthermore, the binding to subtypes other than H5 is significantly lower. Therefore, the antibody according to the present invention and the antibody fragment containing the variable region thereof can detect H5 subtype avian influenza virus specifically, simply and at high sensitivity. Therefore, the antibody according to the present invention can be suitably used in a kit for detecting H5 subtype avian influenza virus, a detection method, and the like.
  • H5 subtype avian influenza virus includes subtypes of N1 to N9, and examples of H5 subtype avian influenza virus used as a target of detection in the present invention include H5N1 subtype, H5N2 subtype and H5N8. There are subtypes.
  • the polynucleotide according to the present invention encodes an antibody fragment comprising the above-mentioned antibody and its variable region.
  • Specific examples of this polynucleotide include the polynucleotides described in any of the following (1) to (4). (1) specifically binding to an HA1 antigen polypeptide having the amino acid sequence shown in SEQ ID NO: 10, having the amino acid sequence shown in SEQ ID NO: 1 or 44 and within the HA1 region of H5 subtype avian influenza virus A polynucleotide encoding an antibody characterized by or an antibody fragment comprising the variable region thereof.
  • (2) has an amino acid sequence in which 1 to 35 amino acids are substituted, deleted, inserted and / or added in the amino acid sequence shown in SEQ ID NO: 1 or 44, and the HA1 region of H5 subtype avian influenza virus Among them, a polynucleotide encoding an antibody or antibody fragment comprising a variable region thereof, which is characterized by specifically binding to an HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10.
  • the number of amino acids substituted, deleted, inserted, and / or added is preferably 1 to 17, preferably 1 to 13, and more preferably 1 to 10. , 1 to 8 is more preferable, 1 to 5 is more preferable, and 1 to 2 or 3 is particularly preferable.
  • HA1 consisting of the amino acid sequence shown in SEQ ID NO: 10, having a sequence identity of 90% or more to the amino acid sequence shown in SEQ ID NO: 1 or 44 and of the HA1 region of H5 subtype avian influenza virus
  • the sequence identity of the amino acid sequence is preferably 95% or more, more preferably 96% or more, and particularly preferably 97% or more, 98% or more, or 99% or more.
  • stringent conditions for example, conditions described in Reference: "Molecular cloning-a Laboratory manual 2nd edition (Sambrook et al., 1989)" can be mentioned. More specifically, under stringent conditions, for example, 6 ⁇ SSC (composition of 1 ⁇ SSC: 0.15 M sodium chloride, 0.015 M sodium citrate, pH 7.0), 0.5% SDS, 5 A condition in which a solution containing ⁇ Denhardt and 100 mg / mL herring sperm DNA is incubated with a probe at 65 ° C.
  • this polynucleotide has 90% or more of sequence identity with the base sequence of the polynucleotide described in the above (1), 95% or more, 96% or more, 97% or more, 98% It is more preferable to have sequence identity of 99% or more.
  • the polynucleotide of the present invention may exist in the form of RNA (eg, mRNA) or in the form of DNA (eg, cDNA or genomic DNA).
  • the DNA may be double stranded or single stranded.
  • An example of the polynucleotide according to the present invention is DNA encoding the polypeptide shown in SEQ ID NO: 1 and SEQ ID NO: 44.
  • An example of the sequence of a polynucleotide encoding the polypeptide shown in SEQ ID NO: 1 is shown in SEQ ID NO: 54
  • an example of the sequence of a polynucleotide encoding the polypeptide shown in SEQ ID NO: 44 is shown in SEQ ID NO: 55.
  • the polynucleotide according to the present invention may contain additional sequences such as untranslated region (UTR) sequences, signal sequences and introns.
  • UTR untranslated region
  • the method for obtaining (isolating) the polynucleotide according to the present invention is not particularly limited.
  • a probe that specifically hybridizes with a part of the base sequence of the above polynucleotide is prepared, and a genome is prepared.
  • the DNA library or cDNA library may be screened.
  • the polynucleotide according to the present invention may be synthesized according to a nucleic acid synthesis method such as the phosphoroamidite method.
  • a method for obtaining the polynucleotide according to the present invention a method using amplification means such as PCR can be mentioned.
  • primers are prepared from the 5 'and 3' sequences (or their complementary sequences) of the cDNA of the polynucleotide, and genomic DNA (or cDNA) or the like is used as a template using these primers.
  • genomic DNA or cDNA or the like is used as a template using these primers.
  • a large amount of DNA fragment containing the polynucleotide according to the present invention can be obtained by performing PCR etc. and amplifying the DNA region sandwiched between both primers.
  • Examples of the polynucleotide according to the present invention further include DNAs encoding the bivalent antibody of the present invention (SEQ ID NOS: 27 and 29 and 53).
  • the polynucleotide (eg, DNA) according to the present invention can also be used as a recombinant vector inserted into a suitable vector.
  • the type of the vector may be, for example, a vector that replicates autonomously (such as a plasmid), or is integrated into the host cell's genome when introduced into a host cell and replicated together with the integrated chromosome. It may be
  • the vector is preferably an expression vector.
  • the polynucleotide according to the present invention is functionally linked to elements necessary for transcription (for example, a promoter and the like).
  • the promoter is a DNA sequence that exhibits transcriptional activity in a host cell, and can be appropriately selected depending on the type of host.
  • Promoters operable in bacterial cells include E. coli lac, trp and tac promoters and the like.
  • promoters operable in insect cells include polh promoter, p10 promoter, and pB1 promoter.
  • promoters operable in yeast cells include promoters derived from yeast glycolytic genes, alcohol dehydrogenase gene promoters, and phosphoglycerate kinase promoters.
  • promoters operable in filamentous fungal cells include the ADH3 promoter, and the tpiA promoter.
  • promoters operable in mammalian cells include SV40 promoter, bovine papilloma virus (BPV) promoter and human cytomegalovirus (CMV) promoter.
  • SV40 promoter bovine papilloma virus (BPV) promoter
  • CMV human cytomegalovirus
  • polynucleotide according to the present invention may optionally be operatively linked to a suitable terminator, such as, for example, a human growth hormone terminator or, for fungal hosts, a TPI1 terminator or an ADH3 terminator.
  • a suitable terminator such as, for example, a human growth hormone terminator or, for fungal hosts, a TPI1 terminator or an ADH3 terminator.
  • the recombinant vector according to the present invention may further have elements such as polyadenylation signal, transcription enhancer sequence and translation enhancer sequence.
  • the recombinant vector according to the present invention may further comprise a DNA sequence enabling the vector to replicate in the host cell, for example the SV40 origin of replication (when the host cell is a mammalian cell) Can be mentioned.
  • the recombinant vector according to the present invention may further contain a selectable marker.
  • a selectable marker for example, drug resistance genes such as ampicillin, kanamycin, tetracycline, chloramphenicol, neomycin or hygromycin can be mentioned.
  • a transformant can be produced by introducing the polynucleotide according to the present invention or the recombinant vector according to the present invention (generally referred to as the nucleic acid construct of the present invention) into a suitable host cell.
  • Host cells include, for example, bacterial cells, yeast cells, fungal cells and higher eukaryotic cells.
  • bacterial cells examples include gram positive bacteria such as Bacillus and Streptomyces or gram negative bacteria such as E. coli. Transformation of these bacterial cells may be performed by, for example, a protoplast method or a method using competent cells.
  • yeast cells include cells of organisms belonging to Saccharomyces or Schizosaccharomyces, such as Saccharomyces cerevisiae and Saccharomyces kluyveri.
  • electroporation, spheroplast method, lithium acetate method and the like can be mentioned.
  • fungal cells other than yeast cells are cells of filamentous fungi, eg, organisms belonging to Aspergillus, Neurospora, Fusarium, or Trichoderma.
  • filamentous fungi eg, organisms belonging to Aspergillus, Neurospora, Fusarium, or Trichoderma.
  • transformation can be performed by integrating the nucleic acid construct of the present invention into a host chromosome to obtain a recombinant host cell. Integration of the nucleic acid construct into the host chromosome can be performed, for example, by homologous recombination or heterologous recombination.
  • Examples of higher eukaryotic cells include plant cells, animal cells and insect cells, and the like, and animal cells further include mammalian cells and avian cells.
  • insect cells examples include Sf9 cells and Sf21 cells.
  • a recombinant gene transfer vector and a baculovirus are co-introduced into the insect cell to obtain a recombinant virus in the insect cell culture supernatant, and the insect cell is further infected with the recombinant virus , Protein can be expressed.
  • a co-introduction method for example, a calcium phosphate method or a lipofection method can be mentioned.
  • plant cells examples include T87 cells.
  • electroporation calcium phosphate method, lipofection method, liposome method, DEAE dextran method, microinjection method and the like can be used for transformation of plant cells.
  • mammalian cells examples include HEK 293 cells, HeLa cells, COS cells, BHK cells, CHL cells, CHO cells, SP2 / 0 cells and NSO cells.
  • mammalian cells When mammalian cells are used as host cells, for example, electroporation, calcium phosphate method, lipofection method, liposome method, DEAE dextran method, microinjection method and the like can be used for transformation of mammalian cells.
  • transformants described above are cultured in an appropriate culture medium under conditions that allow expression of the introduced nucleic acid construct. Then, if necessary, an antibody fragment according to the present invention or an antibody fragment containing the variable region thereof is isolated and purified from a culture of transformants.
  • the transformant is not limited to cells. That is, the transformant may be, for example, a tissue, an organ, and an individual transformed with the nucleic acid construct of the present invention.
  • the non-cell transformant is of non-human origin, and in particular, the individual is preferably of non-human origin.
  • One example of a method for producing an antibody according to the present invention and an antibody fragment containing the variable region thereof is specific to a hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 in the hemagglutinin HA1 region of H5 subtype avian influenza virus It is a method of producing an antibody which binds to the antibody, which comprises the following steps (a) to (c): (a) hemagglutinin consisting of the amino acid sequence shown in SEQ ID NO: 10 Immunizing the bird with an HA1 antigen polypeptide; (b) obtaining a phage antibody library containing a phage antibody that specifically binds to the hemagglutinin HA1 antigen polypeptide from the bird immunized in the step (a); c) Among the phage antibodies obtained in the above step (
  • Step (a) is a step of immunizing birds with an HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10.
  • the method for administering the antigen to birds is not particularly limited.
  • the antigenic polypeptide may be administered intraperitoneally, or the antigenic polypeptide may be administered intravenously.
  • the primary immunization be administered by mixing an equal amount of the antigenic polypeptide and the immunostimulatory agent.
  • immunostimulatory agent for example, those commonly used in the field such as complete Freund's adjuvant, incomplete Freund's adjuvant, or aluminum hydroxide gel adjuvant can be used.
  • a boost (secondary immunization) can be performed 4 weeks after the primary immunization and a boost (third immunization) can be performed 3 to 4 weeks later as an administration interval of the antigenic polypeptide. If serum elevation is not observed, boosting can be performed after 2 to 3 weeks.
  • Birds that immunize the HA1 antigen polypeptide include chicken, ostrich, quail, turkey and the like, with chicken being most preferable in terms of easiness of breeding and securing of feed.
  • Step (b) is a step of obtaining a phage antibody library containing phage antibodies that specifically bind to the antigenic polypeptide from the birds immunized in step (a) above.
  • the method for obtaining an antibody that specifically binds to an antigenic polypeptide is not particularly limited. For example, a method of producing a monoclonal antibody by producing a hybridoma (Reference document: J. Vet. Med. Sci 58 1053 1996) or a method of producing avian phage antibody by phage display (Japanese Patent Application Publication "Patent No. 3908257), etc.). In Examples described later, phage display is used because antibodies can be easily and efficiently produced.
  • a method of obtaining a phage antibody that specifically binds to an HA1 antigen polypeptide using a phage display method is described.
  • the spleen is isolated from the birds immunized in the above step (a), and RNA is extracted from the spleen.
  • RT-PCR is performed using the obtained RNA as a template, and cDNAs containing various heavy chain variable region and light chain variable region genes of the avian antibody are recovered.
  • a plurality of combinations of the obtained heavy chain variable region and light chain variable region genes are linked via a gene encoding a linker ((GGGGS) ⁇ 3) and a gene encoding a spacer (Asp-Val) , Construct a scFv gene.
  • the resulting scFv gene is introduced into a plasmid incorporating avian C ⁇ and the g3p gene to prepare a phagemid vector.
  • the prepared phagemid vector is transformed into a host (eg, E. coli etc.).
  • a host eg, E. coli etc.
  • E. coli transformed with a phagemid vector is further infected with a helper phage.
  • phages expressing scFv can be obtained.
  • panning selection can be performed as a method of concentrating an antibody that specifically binds to the HA1 antigen polypeptide from among a plurality of single-chain phage antibodies (phage antibody library).
  • the method of “panning selection” is not particularly limited.
  • the antigen polypeptide is immobilized on an immuno module plate, and the immobilized antibody polypeptide is reacted with a phage antibody group, and phage not bound is removed by washing. Then, there is a method of repeating several times the operation of eluting only the phages bound to the antigenic polypeptide, infecting E. coli and propagating. By performing panning selection, phages that specifically bind to only the antigenic polypeptide can be enriched.
  • the panning selection operation is preferably repeated once to six times, and more preferably six times.
  • Step (c) is a step of selecting an antibody that specifically binds to the above HA1 antigen polypeptide among the antibodies that specifically bind to the antigen polypeptide obtained in the above step (b).
  • the selection method is not particularly limited, and for example, ELISA method, Western blot method, flow cytometry method, intermolecular interaction analysis and the like can be performed.
  • the above-mentioned solid phase ELISA is performed on the phage antibody concentrated by the above panning selection using the HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 as the solid phase antigen.
  • Antibodies that specifically bind to the HA1 antigen polypeptide can be selected.
  • a step of producing a chicken-type divalent antibody based on the obtained phage antibody producing a chicken-type divalent antibody
  • a step of producing a chimerized antibody having a variable region of a natural chicken antibody for the method of producing a chimerized antibody, see Japanese Patent Laid-Open Publication
  • Japanese Patent Laid-Open Publication No. 2006-282521 and Japanese Patent Laid-Open Publication No. 2005-245337 or a step of preparing a humanized antibody having an antigen-binding region of a chicken natural antibody
  • the method for producing a humanized antibody may include the Japanese Patent Application Publication (JP 2006-241026A).
  • Recombinant vector preferably using the expression vector for H chain and the expression vector for L chain, and introducing the variable region of chicken antibody into them, respectively.
  • a method of expressing in a host mammalian cell can be mentioned.
  • a method including amplification of a target region by PCR using a DNA encoding the obtained phage antibody as a template can be mentioned.
  • random mutagenesis using Inverse PCR or the like, or known mutagenesis, using the obtained phage antibody or a DNA encoding a bivalent or chimeric antibody as a template The method may include the step of mutating the amino acid sequence of the target site by performing point mutation introduction and the like using a method.
  • kits according to the present invention are kits for detecting H5 subtype avian influenza virus contained in a sample, and comprises at least an antibody according to the present invention or an antibody fragment containing a variable region thereof.
  • the antibody according to the present invention and an antibody fragment containing the variable region thereof [1. Antibody according to the present invention].
  • the kit according to the present invention further comprises at least one antibody that recognizes H5 subtype avian influenza virus or an antibody fragment containing the variable region thereof other than the antibody according to the present invention or the antibody fragment containing the variable region thereof.
  • an antibody that specifically binds to an HA2 antigen polypeptide having an amino acid sequence contained in the HA2 region of H5 subtype avian influenza virus and an antibody fragment containing its variable region can be mentioned.
  • an antibody that specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 17 in the HA2 region of H5 subtype avian influenza virus and an antibody fragment containing its variable region can be mentioned.
  • a bivalent anti-HA2 antibody consisting of the amino acid sequence in which the H chain is shown in SEQ ID NO: 18 and an L chain consisting of the amino acid sequence shown in SEQ ID NO: 20 and the H chain in SEQ ID NO: 22
  • the bivalent anti-HA2 antibody which consists of an amino acid sequence shown, and whose L chain consists of an amino acid sequence shown by sequence number 24 is mentioned.
  • a DNA encoding the H chain consisting of the amino acid sequence shown in the above SEQ ID NO: 18 consists of the base sequence shown in SEQ ID NO: 19 and shown in the above SEQ ID NO: 20
  • the DNA encoding the L chain consisting of the amino acid sequence is an anti-HA2 antibody consisting of the base sequence shown in SEQ ID NO: 21
  • the DNA encoding the H chain consisting of the amino acid sequence is an anti-HA2 antibody which comprises a DNA sequence consisting of the nucleotide sequence shown in SEQ ID NO: 23 and encoding an L chain consisting of the amino acid sequence shown above in SEQ ID NO: 24 comprises the nucleotide sequence shown in SEQ ID NO: 25 .
  • the kit according to the present invention includes, in addition to the antibody according to the present invention, a member (secondary antibody, a coloring reagent, a blocking reagent, etc.) necessary for performing an immune reaction such as immunochromatography, ELISA and Western blotting. Plates (96-well plate etc.) and tubes etc. may be included.
  • the membrane, gel for electrophoresis, electrophoresis apparatus, blotting apparatus, reagents for blotting and the like necessary for performing Western blotting may be included.
  • a secondary antibody for detecting the antibody according to the present invention and a substrate of a labeled enzyme bound to the secondary antibody may be provided.
  • the secondary antibody examples include alkaline phosphatase-labeled anti-IgG antibody and horseradish peroxidase (HRP) -labeled anti-IgG antibody.
  • HRP horseradish peroxidase
  • the origin of the anti-IgG antibody to be used is not specifically limited, According to the objective, it selects suitably.
  • a substrate for HRP detection OPD, TMB and ECL (Electro-generated chemiluminescence) etc. can be mentioned, for example.
  • a substrate of alkaline phosphatase for example, a mixed substrate of nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolylphosphatase p-toluidinyl salt (BCIP) can be mentioned.
  • NBT nitroblue tetrazolium
  • BCIP 5-bromo-4-chloro-3-indolylphosphatase p-toluidinyl salt
  • kits eg, vials, tubes, ampoules, bottles, etc.
  • instructions for use in the above kit may be further included.
  • the detection method will be described later [8. Methods for detecting H5 subtype avian influenza virus] can be mentioned.
  • the kit according to the present invention includes, for example, an immunochromatographic kit comprising the antibody according to the present invention, an antibody other than the antibody according to the present invention, and members necessary for enhancing the detection sensitivity.
  • the method for detecting H5 subtype avian influenza virus according to the present invention comprises the step of reacting an antibody according to the present invention or an antibody fragment containing the variable region thereof with a sample prepared from a living body.
  • an antibody according to the present invention [2. Antibody according to the present invention and an antibody fragment containing the variable region thereof].
  • the step of reacting the above-mentioned antibody according to the present invention or the antibody fragment containing the variable region thereof with a sample prepared from the living body is prepared from the living body into a composition containing the antibody according to the present invention or the antibody fragment containing the variable region
  • the method may include the steps of contacting the sample, and detecting a reaction occurring between the sample and a composition containing the antibody or an antibody fragment containing the variable region thereof.
  • Methods used for detection of the above reaction include ELISA, radioimmunoassay, fluorescent immunoassay, western blot, immunochromatography, affinity chromatography, immunoprecipitation, immunodiffusion, hemagglutination inhibition test, etc. Can be mentioned.
  • Examples of methods for detecting the above-mentioned reaction include a sandwich method, a competitive method, a direct adsorption method and the like using an antibody labeled with a labeling agent. By these methods, the amount of the target antigen present in the sample can be measured.
  • the sample used in the detection method according to the present invention is not particularly limited as long as it can contain at least the protein of interest.
  • biological samples include cell samples, tissue samples and wiping fluid samples, and from the viewpoint of the ease of sampling method, wiping fluid samples are preferred.
  • the wiping fluid samples include tracheal wiping fluid, laryngopharyngeal wiping fluid, oral cavity wiping fluid, and wiping solution of the general excretory space of birds.
  • Organisms from which a biological sample is derived include, for example, mammals such as birds, humans and pigs. Among these, preferably, it is a bird, and among the birds, more preferably a fowl chicken.
  • the collected biological sample may be subjected to a test after extracting the protein as necessary or after removing an unnecessary component.
  • the obtained biological sample may be stored by a method suitable for the type of biological sample, such as cryopreservation, if necessary.
  • the detection method according to the present invention is a reaction between a sample prepared from a living body and an antibody fragment containing at least one type of antibody that recognizes H5 subtype avian influenza virus or its variable region other than the antibody according to the present invention
  • the method may further comprise the step of With respect to antibodies other than the antibody according to the present invention and the antibody fragment containing the variable region thereof and the antibody fragment containing the variable region [7. Kit according to the present invention].
  • the test method according to the present invention further determines the presence or absence of a virus in the biological sample, or the amount of H5 subtype avian influenza virus in the biological sample, more specifically, per unit amount of biological sample.
  • the method may include the step of measuring the amount of H5 subtype avian influenza virus included.
  • the amount of H5 subtype avian influenza virus is, for example, the amount of H5 subtype avian influenza virus protein.
  • the concept of measuring the amount of H5 subtype avian influenza virus contained per unit amount of biological sample includes both quantitative measurement and qualitative measurement, and in addition to concentration measurement, a format comparable to a control It includes presenting the amount of H5 subtype avian influenza virus. More specifically, for example, data comparison before acquisition of concentration conversion using a calibration curve or the like, or in the form of whether the amount of H5 subtype avian influenza virus exceeds a certain threshold or not The presentation of the results of
  • the method for detecting H5 subtype avian influenza virus according to the present invention may include the step of determining the possibility of infection of H5 subtype avian influenza virus in a subject individual.
  • determining the possibility of infection with the H5 subtype avian influenza virus means that the target individual is infected with the influenza virus regardless of whether or not the influenza has developed. Indicates to determine whether or not.
  • avian influenza in chickens include symptoms such as depression, flesh crown, pits and legs cyanosis, facial edema, neurological symptoms, feathering, and diarrhea.
  • a step of determining whether or not the H5 subtype avian influenza virus is excreted is mentioned as the step of the determination.
  • the method of judging by visual observation of the data of color development and numerical value etc. which were obtained in the method used in the process of detecting H5 subtype avian influenza virus mentioned above is mentioned about the virus-derived substance which has been developed .
  • the test individual when the amount of the virus in the biological sample of the test individual exceeds a predetermined threshold value as compared to a healthy control, the test individual is excreting the virus by H5 subtype avian influenza virus infection It is determined that Incidentally, the fact that the amount of virus exceeds a predetermined threshold value may be a result of quantitative measurement or a result of qualitative measurement, and it is needless to say that the comparison of specific numerical values is a relative amount of It is a concept that includes comparison (it is not necessary to actually calculate the amount, and it is determined whether it is higher or lower than a certain standard).
  • the above test of the control sample may be performed simultaneously with the test of the sample of the test individual, or may be performed separately. That is, the numerical value of the control sample to be compared with the numerical value of the test individual may be the value obtained in the test performed when the sample of the test individual is different from when it is tested.
  • the test of the control sample does not have to be performed by the individual who tests the test individual, and for example, the test value of the control sample already acquired and accumulated in a database or the like can be used as a threshold.
  • the numerical value of the sample of the healthy individual may be used directly, or the average value obtained when the numerical value of the sample of the healthy individual of a certain number is used as the population It is also good.
  • a cutoff value may be set in advance, and the numerical value of the test individual may be compared with this cutoff value.
  • the H5 subtype avian influenza virus contained in a sample is specifically, accurately, rapidly and highly sensitively detected than the existing detection method. Can.
  • the present invention includes any one of the following aspects.
  • the heavy chain variable region includes all of CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5 and CDR3 shown in SEQ ID NO: 6 or SEQ ID NO: 46, and a light chain variable region
  • the heavy chain variable region is substituted, deleted, inserted, and / or added with 1 to 13 amino acids in the amino acid sequence shown in SEQ ID NO: 2 or the amino acid sequence shown in SEQ ID NO: 2 1 to 10 amino acids are substituted, deleted, inserted, and / or made up of the amino acid sequence, and the light chain variable region is the amino acid sequence shown in SEQ ID NO: 3 or the amino acid sequence shown in SEQ ID NO: 3
  • An antibody fragment comprising the antibody according to ⁇ 1> or ⁇ 2>, or a variable region thereof, characterized in that it comprises an added amino acid sequence.
  • ⁇ 4> The antibody according to ⁇ 3>, wherein the heavy chain variable region consists of the amino acid sequence shown in SEQ ID NO: 45, and the light chain variable region consists of the amino acid sequence shown in SEQ ID NO: 3 Or an antibody fragment comprising the variable region thereof.
  • ⁇ 5> Of the hemagglutinin HA1 region of the H5 subtype avian influenza virus shown in any of the following (1) to (4), specifically to the hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10
  • An antibody fragment or antibody fragment according to any one of ⁇ 1> to ⁇ 4> characterized in that it binds: (1) an antibody consisting of the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 44 or An antibody fragment comprising the variable region, (2) an antibody comprising an amino acid sequence in which 1 to 35 amino acids are substituted, deleted, inserted and / or added in the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 44
  • An antibody fragment containing the variable region (3) 90% or more sequence identity to the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 44
  • the present invention is directed to a polynucleotide comprising a sequence complementary to the polynucleot
  • An antibody consisting of an amino acid sequence encoded by a polynucleotide hybridizing under various conditions or an antibody fragment comprising the variable region thereof.
  • ⁇ 7> An antibody fragment comprising the antibody according to any one of ⁇ 1> to ⁇ 6> or a variable region thereof, which is a single-chain variable region fragment or a bivalent antibody.
  • ⁇ 8> The bivalent antibody according to ⁇ 1>, wherein the heavy chain consists of the amino acid sequence shown in SEQ ID NO: 26 or 52, and the light chain consists of the amino acid sequence shown in SEQ ID NO: 28; An antibody fragment comprising the antibody or the variable region thereof described in any of ⁇ 7>.
  • ⁇ 9> A polynucleotide encoding the antibody according to any one of ⁇ 1> to ⁇ 8> or an antibody fragment containing the variable region thereof.
  • ⁇ 10> A recombinant vector comprising the polynucleotide according to ⁇ 9>.
  • ⁇ 11> A transformant, wherein the polynucleotide according to ⁇ 9> or the recombinant vector according to ⁇ 10> is introduced.
  • a method for producing an antibody that specifically binds to a hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 of the hemagglutinin HA1 region of H5 subtype avian influenza virus which comprises the following (a A) a method comprising the steps of (c): (a) immunizing the avian hemagglutinin HA1 antigen polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 10 with a bird; (b) the above step (a) Obtaining a phage antibody library comprising a phage antibody which specifically binds to the above-mentioned hemagglutinin HA1 antigen polypeptide from the birds immunized with the above; and (c) the above-mentioned hemagglutinin HA1 among the phage antibodies obtained in the above step (b) Concentrating and selecting antibodies that specifically bind to the antigenic polypeptide.
  • ⁇ 13> The method according to ⁇ 12>, wherein the antibody is a single chain variable region fragment or a bivalent antibody.
  • ⁇ 14> A polypeptide comprising the amino acid sequence shown in SEQ ID NO: 10.
  • ⁇ 15> A kit for detecting H5 subtype avian influenza virus contained in a sample, comprising an antibody according to any one of ⁇ 1> to ⁇ 8> or an antibody fragment containing a variable region thereof
  • a kit that is characterized by ⁇ 16> A method for detecting H5 subtype avian influenza virus contained in a sample, comprising: the antibody according to any one of ⁇ 1> to ⁇ 8> or an antibody fragment containing the variable region thereof Reacting the sample with the sample.
  • ⁇ 17> The method according to ⁇ 16>, wherein the sample is a swab of trachea, laryngopharynx, oral cavity or common excretory.
  • ⁇ 20> The antibody fragment according to ⁇ 18> or ⁇ 19>, or a variable region thereof, wherein the H5 subtype avian influenza virus is an H5N1 avian influenza virus.
  • ⁇ 21> Any one of ⁇ 18> to ⁇ 20>, which specifically binds to the region represented by the amino acid sequence shown in SEQ ID NO: 10 in the hemagglutinin HA1 region of H5 subtype avian influenza virus An antibody fragment comprising the described antibody or its variable region.
  • FIG. 1 is a diagram showing one step in the method for producing an antibody, and shows the steps for producing a scFv phage antibody library from the above-described chicken immunity and immune chicken spleen.
  • ⁇ Panning selection> The scFv phage antibody library was used to perform panning on a plate on which a synthetic peptide was immobilized. Panning was performed according to the method described in the reference: "Nakamura et al., J Vet Med Sci. 2004 Ju; 66 (7): 807-814". After five rounds of panning, the reactivity of the library was confirmed by ELISA using a plate on which a synthetic peptide was immobilized, and phages were screened from the library whose reactivity began to increase. The screening method is as follows. The phage was infected into E.
  • FIG. 2 is a diagram showing one step in the method for producing an antibody, and shows a step of panning selection of scFv phage library.
  • the screening was performed using the ELISA method shown in the item of ⁇ ELISA> below.
  • ⁇ ELISA> For screening, PBS containing 5 ⁇ g / ml of synthetic peptide was placed at 50 ⁇ l / well in a 96-well plate (442404, Thermo), and the antigen was immobilized overnight at 4 ° C. After immobilization, the wells were blocked with PBS containing 25% Block Ace (UK-B80, DS Pharma Biomedical), and the culture supernatant containing the scFv phage antibody was reacted.
  • PBS containing 5 ⁇ g / ml of synthetic peptide was placed at 50 ⁇ l / well in a 96-well plate (442404, Thermo), and the antigen was immobilized overnight at 4 ° C. After immobilization, the wells were blocked with PBS containing 25% Block Ace (UK-B80, DS Pharma Biomedical), and the culture supernatant containing the scFv phage antibody was reacted.
  • FIG. 3 is a diagram showing one step in the method for producing an antibody according to an example of the present invention, and shows a step of screening a scFv phage library using ELISA.
  • FIG. 4 is a diagram showing the variable region of the amino acid sequence of the obtained antibody.
  • Example 1 the amino acid sequence of full length L chain is shown in SEQ ID NO: 28 and the base sequence of full length L chain is shown in SEQ ID NO: 29
  • SEQ ID NO: 28 the sequence of No. 6-2-5 obtained in Example 1 is referred to as wild type, and a sequence obtained by modifying the same in Example 2 below is described as a variant type sequence.
  • FIG. 5 is a diagram showing one step in the method for producing an antibody, and shows steps for producing a bivalent antibody by recombination into a bivalent antibody expression vector.
  • the resulting purified antibody was subjected to SDS-PAGE electrophoresis using 5-20% c-Page (C520L, ATTO), and the degree of purification was confirmed by CBB staining (178-00551, Wako).
  • FIG. 6 shows the results of CBB staining of wild-type bivalent antibody protein after electrophoresis.
  • the antibody titer was measured as follows. Similarly, PBS containing 5 ⁇ g / ml of recombinant hemagglutinin (rHA) (derived from H5N1 virus, A / Vietnam / 1203/2004, CT6450, Protein Sciences Corp.) or bovine serum albumin (BSA (bovine serum albumin)) was similarly immobilized After blocking, purified mouse / chicken chimeric antibody (No. 6-2-5) was reacted at a concentration of 0 to 2 ⁇ g / ml.
  • rHA recombinant hemagglutinin
  • BSA bovine serum albumin
  • FIG. 7 shows the antibody titer of a wild-type bivalent antibody.
  • FIG. 8 shows antibody binding to wild-type bivalent antibody H5N1 avian influenza virus variants and to a plurality of H5 avian influenza virus subtypes other than H5.
  • the purified wild-type bivalent antibody (No. 6-2-5) obtained in this example has almost no binding ability to avian influenza virus except subtype H5, It also showed high binding ability and specificity to the H5 subtype avian influenza virus.
  • Example 2 Preparation of Mutant Antibody and Evaluation of Reactivity (2-1. Preparation of antibody) ⁇ Preparation of mutant library> Using the H chain of the above-mentioned clone No. 6-2-5 as a template, random mutations in which 9 base random mutations were introduced into CDR3 of the H chain of No. 6-2-5 using Inverse PCR method were used. Seven types were prepared (SMK-101, TOYOBO). The primer sets used are shown in SEQ ID NOS: 30-43.
  • variable regions of the H chain and the variable region of the L chain of the seven random variants obtained were amplified by PCR, respectively, and joined with a linker to prepare a scFv phage library.
  • the details of the method of preparing the scFv phage library were performed according to the method described in the reference: "Nakamura et al., J Vet Med Sci. 2004 Ju; 66 (7): 807-814".
  • ⁇ Panning selection> The scFv phage antibody library was used to perform panning against rHA (11700-V08H, Sino Biological Inc.). Panning was performed according to the method described in the reference: "Nakamura et al., J Vet Med Sci. 2004 Ju; 66 (7): 807-814". After 4 rounds of panning, the increase in reactivity was confirmed by ELISA. Screening was performed from the second round of panning library whose reactivity has been increased. The screening was performed using the same method as that described in (1-1. Preparation of antibody) in ⁇ Example 1> ⁇ Panningselection>.
  • Sequence confirmation was performed by outsourcing (Eurofin Genomics). As a result, acquisition of an antibody of a novel sequence was confirmed.
  • the amino acid sequence of full length single chain antibody of newly obtained clone No. 6-2-5-21 is shown in SEQ ID NO: 44.
  • the sequence of No. 6-2-5-21, which is a newly obtained clone, had the same sequence as that of No. 6-2-5 except for the sequence of CDR3 of the H chain.
  • the amino acid sequence of the H chain variable region of No. 6-2-521 is shown in SEQ ID NO: 45, the amino acid sequence of CDR3 in SEQ ID NO: 46, and the base sequence of CDR3 in SEQ ID NO: 47.
  • FIG. 9 is a diagram showing an alignment of the amino acid sequence of the CDR3 of the H chain of wild type antibody No. 6-2-5 with the amino acid sequence of the CDR3 of the H chain of mutant antibody No. 6-2-5-21. is there.
  • mouse / chicken chimeric antibody (IgG1) expression vector H chain expression vector: restriction vector treated with SacII (R0157S, BioLabs) and NheI (R0131S, BioLabs) expression vector: pcDNA4 / myc-His, L chain expression vector: Recombination into pcDNA3 / myc-His, Invitrogen) using GeneArt® Seamless Cloning and Assembly (A14606, lifetechnologies).
  • the mouse chimeric expression vector used was the vector described in Tateishi et al., J Vet Med Sci. 2008 Apr; 70 (4): 397-400.
  • the sequences of the variable region amplification primers are shown in SEQ ID NOs: 48 to 51.
  • FIG. 10 is a diagram showing the antibody titer of a mutated bivalent antibody.
  • Biacore T200 Biacore T200, GE Healthcare
  • Biacore T200 Biacore T200, GE Healthcare
  • the affinity was measured using Mouse Antibody Capture Kit (BR-1008-38, GE Healthcare) .
  • a rabbit anti-mouse polyclonal antibody was immobilized on the surface of the CM5 chip by amine coupling using free carboxyl groups on the surface of the CM5 chip using NHS / EDC according to a standard protocol provided by the manufacturer.
  • Nos. 6-2-5 and 6-2-5-21 were captured on rabbit anti-mouse polyclonal antibodies.
  • Different concentrations of rHA were applied to Biacore T200 to generate kinetic sensorgrams and to calculate binding constants. The results are shown in Table 1 below.
  • FIG. 11 is a view showing antibody binding of each of the mutant bivalent antibodies to each of the avian influenza viruses.
  • the three-dimensional structure analysis software Pymol (web page: http://www.pymol.org/) was used, and the H5 subtype registered in the protein data bank (web page: http://pdbj.org/)
  • the three-dimensional structure of HA protein (PDB ID: 2IBX) was compared with the sequence of the amino acid of H5 subtype.
  • FIG. 12 shows the sequence (right) of a synthetic polypeptide used as an antigen of H5N1 avian influenza virus, and the three-dimensional structure (left) of an HA protein.
  • the amino acid sequence consisting of 16 amino acids shown as SEQ ID NO: 10 is a clade 0-9 different in H5N1 subtype in the HA1 region. It was saved among the stocks of In addition, this amino acid sequence was conserved in 99.4% of H5 subtypes of 2812 strains isolated after 1997 registered in NCBI.
  • amino acid sequence consisting of 16 amino acids was highly retained between strains different in H5 subtype, and appeared on the surface of the protein in terms of conformation.
  • H1 to H16 subtype avian influenza viruses 8781 for H1 subtypes from NCBI influenza virus resources (web page: http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) H2 subtype 231, H3 subtype 4536, H4 subtype 608, H5 subtype 2812, H6 subtype 687, H7 subtype 787, H8 subtype 65, 739 for H9 subtype, 190 for H10 subtype, 187 for H11 subtype, 84 for H12 subtype, 53 for H13 subtype, 4 for H14 subtype, 12 for H15 subtype, H16 The amino acid sequence of the full-length HA gene of 19 avian influenza viruses was obtained for the subtype.
  • FIG. 13 is a diagram showing sequence identity among all subtypes of H1-H16 subtype avian influenza virus and among all clades present in H5N1 subtype avian influenza virus.
  • A shows sequence identity among all subtypes in H1-H16 subtype avian influenza virus
  • b shows sequence identity among all clades present in H5N1 subtype avian influenza virus Show the sex.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　Afin de fournir un anticorps ou fragment d'anticorps comprenant la région variable dudit anticorps pour les sous-types H5 du virus de la grippe aviaire, un polypeptide antigénique, et les utilisations de ceux-ci, la présente invention concerne : un anticorps ou un fragment d'anticorps comprenant la région variable dudit anticorps, qui se lie spécifiquement au polypeptide antigénique HA1 de la région HA1 des sous-types H5 du virus de la grippe aviaire, ledit polypeptide antigénique comprenant la séquence d'acides aminés représentée par la SEQ ID n° 10 ; le polypeptide antigénique HA1 comprenant la séquence d'acides aminés représentée par la SEQ ID n° 10 ; et les utilisations de l'anticorps et du fragment d'anticorps comprenant la région variable de l'anticorps.
PCT/JP2015/065986 2014-06-03 2015-06-03 Anticorps ou fragment d'anticorps comprenant une région variable de celui-ci, polypeptide antigénique et utilisations de ceux-ci WO2015186721A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016525195A JP6525214B2 (ja) 2014-06-03 2015-06-03 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014-115221 2014-06-03
JP2014115221 2014-06-03

Publications (1)

Publication Number Publication Date
WO2015186721A1 true WO2015186721A1 (fr) 2015-12-10

Family

ID=54766790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/065986 WO2015186721A1 (fr) 2014-06-03 2015-06-03 Anticorps ou fragment d'anticorps comprenant une région variable de celui-ci, polypeptide antigénique et utilisations de ceux-ci

Country Status (2)

Country Link
JP (1) JP6525214B2 (fr)
WO (1) WO2015186721A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108484759A (zh) * 2018-03-01 2018-09-04 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
CN112194722A (zh) * 2020-09-10 2021-01-08 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 抗h5亚型禽流感病毒的重组抗体及其制备方法和应用
US20210277147A1 (en) * 2018-09-04 2021-09-09 Sino-Swed Tongkang Bio-Tech (Shenzhen) Limited Development of recombinant chicken igy monoclonal antibody and scfv antibodies raised against human tymidine kinase 1 expressed in mammalian cells and use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021002A1 (fr) * 2005-08-19 2007-02-22 Bl Co., Ltd. Méthode d’immunodétection pour le sous-type h5 du virus de la grippe
WO2008039267A2 (fr) * 2006-07-21 2008-04-03 Pharmexa Inc. Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques
JP2008196967A (ja) * 2007-02-13 2008-08-28 Bl:Kk インフルエンザウイルスｈ５亜型の免疫検出法
JP2009524434A (ja) * 2006-01-26 2009-07-02 エイチエックス・ダイアグノスティックス・インコーポレイテッド トリインフルエンザウイルス亜型ｈ５ヘマグルチニンに結合するモノクローナル抗体およびそれらの使用
WO2009119722A1 (fr) * 2008-03-28 2009-10-01 国立大学法人北海道大学 Anticorps monoclonal anti-(hémagglutinine du sous-type h5 du virus de la grippe de type a)
JP2011506344A (ja) * 2007-12-06 2011-03-03 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド インフルエンザウイルスに対する抗体およびその使用方法
JP2011514321A (ja) * 2008-02-05 2011-05-06 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５亜型インフルエンザウイルスの普遍的な検出のための結合タンパク質およびエピトープブロッキングｅｌｉｓａ
JP2013087069A (ja) * 2011-10-17 2013-05-13 Toyobo Co Ltd Ｈ５亜型インフルエンザウイルスを特異的に認識するモノクローナル抗体
WO2013122827A1 (fr) * 2012-02-13 2013-08-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antigènes largement réactifs optimisés par ordinateur pour la grippe h5n1 humaine et aviaire

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021002A1 (fr) * 2005-08-19 2007-02-22 Bl Co., Ltd. Méthode d’immunodétection pour le sous-type h5 du virus de la grippe
JP2009524434A (ja) * 2006-01-26 2009-07-02 エイチエックス・ダイアグノスティックス・インコーポレイテッド トリインフルエンザウイルス亜型ｈ５ヘマグルチニンに結合するモノクローナル抗体およびそれらの使用
WO2008039267A2 (fr) * 2006-07-21 2008-04-03 Pharmexa Inc. Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques
JP2008196967A (ja) * 2007-02-13 2008-08-28 Bl:Kk インフルエンザウイルスｈ５亜型の免疫検出法
JP2011506344A (ja) * 2007-12-06 2011-03-03 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド インフルエンザウイルスに対する抗体およびその使用方法
JP2011514321A (ja) * 2008-02-05 2011-05-06 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５亜型インフルエンザウイルスの普遍的な検出のための結合タンパク質およびエピトープブロッキングｅｌｉｓａ
WO2009119722A1 (fr) * 2008-03-28 2009-10-01 国立大学法人北海道大学 Anticorps monoclonal anti-(hémagglutinine du sous-type h5 du virus de la grippe de type a)
JP2013087069A (ja) * 2011-10-17 2013-05-13 Toyobo Co Ltd Ｈ５亜型インフルエンザウイルスを特異的に認識するモノクローナル抗体
WO2013122827A1 (fr) * 2012-02-13 2013-08-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antigènes largement réactifs optimisés par ordinateur pour la grippe h5n1 humaine et aviaire

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
HA Y ET AL.: "H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes", EMBO J., vol. 21, no. 5, 2002, pages 865 - 875, XP008160405 *
HE F ET AL.: "Complementary monoclonal antibody- based dot ELISA for universal detection of H5 avian influenza virus", BMC MICROBIOL., vol. 10, 2010, pages 330, XP021086589 *
HITOSHI TAKAHASHI ET AL.: "H5HA Tokuitei na Monoclonal Kotai no Sakusei to H5N1 Influenza Jinsoku Shindanho Kochiku no Kento", THE JAPANESE SOCIETY OF VIROLOGY GAKUJUTSU SHUKAI PROGRAM SHOROKU-SHU, vol. 61, 29 October 2013 (2013-10-29), pages 431 *
HO HT ET AL.: "Rapid detection of H5N1 subtype influenza viruses by antigen capture enzyme- linked immunosorbent assay using H5- and N1- specific monoclonal antibodies", CLIN. VACCINE IMMUNOL., vol. 16, no. 5, 2009, pages 726 - 732, XP055023724 *
KOBAYASHI-ISHIHARA M ET AL.: "Broad cross- reactive epitopes of the H5N1 influenza virus identified by murine antibodies against the A/ Vietnam /1194/2004 hemagglutinin", PLOS ONE, vol. 9, no. 6, 19 June 2014 (2014-06-19), pages e99201, XP002740276 *
MIE KOBAYASHI (ISHIHARA ET AL.: "H5N1 Influenza Virus Kokando Kenshutsukei Kaihatsu ni Muketa H5HA Tokuiteki Kotai no Epitope Kaiseki", THE JAPANESE SOCIETY OF VIROLOGY GAKUJUTSU SHUKAI PROGRAM SHOROKU-SHU, vol. 61, 29 October 2013 (2013-10-29), pages 208 *
TSUDA Y ET AL.: "Development of an immunochromatographic kit for rapid diagnosis of H5 avian influenza virus infection", MICROBIOL. IMMUNOL., vol. 51, no. 9, 2007, pages 903 - 907, XP002526101 *
YANG JP ET AL.: "Characterization of human single-chain antibodies against highly pathogenic avian influenza H5N1 viruses: mimotope and neutralizing activity", J. BIOCHEM., vol. 148, no. 4, 2010, pages 507 - 515, XP055240120 *
YANG M ET AL.: "Production and diagnostic application of monoclonal antibodies against influenza virus H5", J. VIROL. METHODS., vol. 162, no. 1-2, 2009, pages 194 - 202, XP026682339 *
YUJI SHOYA ET AL.: "H5 Agata Ko-Byogensei Tori Influenza Virus no Jinsoku Shindan Kit no Kaihatsu", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY TAIKAI KOEN YOSHISHU, vol. 2015, 5 March 2015 (2015-03-05), pages 2C25p17 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108484759A (zh) * 2018-03-01 2018-09-04 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
US20210277147A1 (en) * 2018-09-04 2021-09-09 Sino-Swed Tongkang Bio-Tech (Shenzhen) Limited Development of recombinant chicken igy monoclonal antibody and scfv antibodies raised against human tymidine kinase 1 expressed in mammalian cells and use thereof
CN112194722A (zh) * 2020-09-10 2021-01-08 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 抗h5亚型禽流感病毒的重组抗体及其制备方法和应用

Also Published As

Publication number Publication date
JPWO2015186721A1 (ja) 2017-04-20
JP6525214B2 (ja) 2019-06-05

Similar Documents

Publication Publication Date Title
CA2809780C (fr) Anticorps neutralisant le virus de la grippe et son procede de criblage
KR101421460B1 (ko) Ｈ５ 조류 인플루엔자 진단 및 감시를 위해 유용한 ｈ５ 서브타입-특이적 결합 단백질
KR20100124720A (ko) 항 ｈ5 아형 ａ형 인플루엔자 바이러스 헤마글루티닌 모노클로날 항체
KR20160054161A (ko) 중증 열성 혈소판 감소 증후군 바이러스 감염 진단용 단클론항체, 이를 생산하는 하이브리도마 및 이 단클론항체를 사용하는 중증 열성 혈소판 감소 증후군 바이러스 감염 진단방법
US10696737B2 (en) Monoclonal antibodies against hemagglutinin of h5-serotype influenza viruses and their uses, hybridomas producing said antibodies, compositions and diagnostic kits
CN110684740B (zh) 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用
JPH07304799A (ja) 抗ヒトインフルエンザウイルス抗体
KR101652962B1 (ko) 돼지열병 바이러스 생마커백신주 접종 돼지와 돼지열병 바이러스 야외주 감염 돼지의 항체 감별용 키트 및 이를 이용한 감별방법
CN109081868B (zh) 靶向寨卡病毒包膜蛋白保守表位的单克隆抗体及其应用
JP6525214B2 (ja) 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用
CN112521496A (zh) 特异性结合SARS-CoV-2 Spike RBD 的单克隆抗体及其应用
CN110373393B (zh) 一种分泌抗传染性法氏囊病毒vp2蛋白单克隆抗体的杂交瘤细胞株1h6
CN114088941B (zh) 一种检测猪急性腹泻综合征冠状病毒的双抗体夹心elisa试剂盒
WO2015199618A1 (fr) Anticorps spécifique de lmp2 du virus d'epstein-barr et ses utilisations
CN106701687B (zh) 一种杂交瘤细胞株及其产生的狂犬病毒磷蛋白单克隆抗体
Bai et al. Characterization of monoclonal antibodies against duck Tembusu virus E protein: an antigen-capture ELISA for the detection of Tembusu virus infection
KR101821956B1 (ko) 인플루엔자 a 바이러스의 뉴클레오단백질에 특이적인 단클론항체 및 이를 이용한 신속 형광면역 진단키트
CN109111507B (zh) 病毒重组糖蛋白及其真核细胞高效表达方法与应用
CN101591390B (zh) 抗h5n1来源的禽流感病毒核蛋白np的单克隆抗体及其应用
CN110885372A (zh) 一种抗念珠菌甘露聚糖的兔源单克隆抗体及其应用
US20170121373A1 (en) Expression and conformational analysis of engineered influenza hemagglutinin
CN112359020B (zh) 一种杂交瘤细胞株、类禽型H1N1猪流感病毒HA蛋白MAb、抗原表位及应用
JP2007285749A (ja) インフルエンザ感染検査薬及び検査方法
KR102196159B1 (ko) 조류 인플루엔자 바이러스 h7 아형의 헤마글루티닌에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN107254448B (zh) 鸭抗原转运相关蛋白tap2单克隆抗体及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15803728

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016525195

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15803728

Country of ref document: EP

Kind code of ref document: A1